543 related articles for article (PubMed ID: 12001111)
21. Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma.
Prasad R; Boland GP; Cramer A; Anderson E; Knox WF; Bundred NJ
Cancer; 2003 Dec; 98(12):2539-46. PubMed ID: 14669271
[TBL] [Abstract][Full Text] [Related]
22. Comparison between Ki-67 index and S-phase fraction on fine-needle aspiration samples from breast carcinoma.
Bozzetti C; Nizzoli R; Camisa R; Guazzi A; Ceci G; Cocconi G; Mazzini G; Naldi N
Cancer; 1997 Oct; 81(5):287-92. PubMed ID: 9349516
[TBL] [Abstract][Full Text] [Related]
23. The role of MIB-1 index in the prognosis of resectable pancreatic head cancer.
Shyr YM; Su CH; Li AF; Wu CW; Lui WY
Hepatogastroenterology; 1999; 46(29):2968-73. PubMed ID: 10576384
[TBL] [Abstract][Full Text] [Related]
24. Pleomorphic lobular carcinoma in situ (PLCIS) on breast core needle biopsies: clinical significance and immunoprofile.
Chivukula M; Haynik DM; Brufsky A; Carter G; Dabbs DJ
Am J Surg Pathol; 2008 Nov; 32(11):1721-6. PubMed ID: 18769331
[TBL] [Abstract][Full Text] [Related]
25. E2F-1: a proliferative marker of breast neoplasia.
Zhang SY; Liu SC; Al-Saleem LF; Holloran D; Babb J; Guo X; Klein-Szanto AJ
Cancer Epidemiol Biomarkers Prev; 2000 Apr; 9(4):395-401. PubMed ID: 10794484
[TBL] [Abstract][Full Text] [Related]
26. Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer.
Wolf G; Hildenbrand R; Schwar C; Grobholz R; Kaufmann M; Stutte HJ; Strebhardt K; Bleyl U
Pathol Res Pract; 2000; 196(11):753-9. PubMed ID: 11186170
[TBL] [Abstract][Full Text] [Related]
27. Intraductal spread of invasive breast carcinoma has a positive correlation with c-erb B-2 overexpression and vascular invasion.
Jing X; Kakudo K; Murakami M; Nakamura Y; Nakamura M; Yokoi T; Yang Q; Oura S; Sakurai T
Cancer; 1999 Aug; 86(3):439-48. PubMed ID: 10430252
[TBL] [Abstract][Full Text] [Related]
28. [Male breast cancer. Histochemical and flow cytometry analysis of 6 cases].
Galasso MG; Galia A; Gazzano G; Cosentino A; Castorina S
Pathologica; 1995 Oct; 87(5):503-5. PubMed ID: 8868175
[TBL] [Abstract][Full Text] [Related]
29. Analysis of relative proliferation rates of Wilms' tumor components using proliferating cell nuclear antigen and MIB-1 (Ki-67 equivalent antigen) immunostaining and assessment of mitotic index.
Khine MM; Aung W; Sibbons PD; Howard CV; Clapham E; McGill F; Van Velzen D
Lab Invest; 1994 Jan; 70(1):125-9. PubMed ID: 7905542
[TBL] [Abstract][Full Text] [Related]
30. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters.
McKeever PE; Ross DA; Strawderman MS; Brunberg JA; Greenberg HS; Junck L
J Neuropathol Exp Neurol; 1997 Jul; 56(7):798-805. PubMed ID: 9210876
[TBL] [Abstract][Full Text] [Related]
31. Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers.
Moreno A; Lloveras B; Figueras A; Escobedo A; Ramon JM; Sierra A; Fabra A
Mod Pathol; 1997 Nov; 10(11):1088-92. PubMed ID: 9388058
[TBL] [Abstract][Full Text] [Related]
32. Mib-1 proliferation index is an independent predictor of lymph node metastasis in invasive breast cancer: a prospective study on 675 patients.
Marrelli D; Pinto E; Neri A; Megha T; Gioffrè W; Cioppa T; De Marco G; De Stefano A; Roviello F
Oncol Rep; 2006 Feb; 15(2):425-9. PubMed ID: 16391864
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution.
Intra M; Rotmensz N; Viale G; Mariani L; Bonanni B; Mastropasqua MG; Galimberti V; Gennari R; Veronesi P; Colleoni M; Tousimis E; Galli A; Goldhirsch A; Veronesi U
Cancer; 2004 Sep; 101(5):905-12. PubMed ID: 15329896
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
[TBL] [Abstract][Full Text] [Related]
35. Proliferation index determined by MIB-1 and recurrence in endometrial cancer.
Geisler JP; Wiemann MC; Zhou Z; Miller GA; Geisler HE
Gynecol Oncol; 1996 Jun; 61(3):373-7. PubMed ID: 8641618
[TBL] [Abstract][Full Text] [Related]
36. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
37. Pathology and behavior of small breast carcinomas.
Meyer JS; Fahrner M; Daniel FC
Semin Diagn Pathol; 1999 Aug; 16(3):257-68. PubMed ID: 10490202
[TBL] [Abstract][Full Text] [Related]
38. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M
Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
[TBL] [Abstract][Full Text] [Related]
39. The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer.
Jensen V; Ladekarl M; Holm-Nielsen P; Melsen F; Soerensen FB
J Pathol; 1995 Aug; 176(4):343-52. PubMed ID: 7562249
[TBL] [Abstract][Full Text] [Related]
40. Comparative investigation of proliferation markers and their prognostic relevance in human meningiomas.
Torp SH; Lindboe CF; Granli US; Moen TM; Nordtømme T
Clin Neuropathol; 2001; 20(5):190-5. PubMed ID: 11594503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
